Skip to main content
Alpha Cognition Inc. logo

Alpha Cognition Inc. — Investor Relations & Filings

Ticker · ACOG ISIN · CA02074J2048 LEI · 254900J4A8UTBGYKPA90 US Manufacturing
Filings indexed 174 across all filing types
Latest filing 2025-02-13 Major Shareholding Noti…
Country CA Canada
Listing US ACOG

About Alpha Cognition Inc.

https://www.alphacognition.com/

Alpha Cognition Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing treatments for patients with neurodegenerative diseases. The company's primary focus is on conditions such as Alzheimer's disease and amyotrophic lateral sclerosis (ALS). Its lead product, ZUNVEYL® (benzgalantamine), is a novel cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer’s type. ZUNVEYL is designed with an optimized drug delivery system to improve patient outcomes and address underserved needs in neurological health.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2025
Major Shareholding Notification
2025-02-13 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-02-01 English
PROSPECTUS
Regulatory Filings
2025-01-15 English
PROSPECTUS
Regulatory Filings
2025-01-15 English
Regulatory Filings 2025
Regulatory Filings
2025-01-14 English
Regulatory Filings 2025
Regulatory Filings
2025-01-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.